3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
38
Lung Neoplasms
9
Adenocarcinoma of Lung
9
NSCLC
5
Brain Neoplasms
5
Adenocarcinoma, Bronchiolo-Alveolar
3
Neoplasms
2
Adenocarcinoma
2
Triple Negative Breast Neoplasms
1
Skin Neoplasms
1
Non-squamous Non-small Cell Lung Cancer
1
Non-Small-Cell Lung
1
Liver Neoplasms
1
Gastrointestinal Neoplasms
1
Gallbladder Neoplasms
1
Esophageal Neoplasms
1
EGFR Tyrosine Kinase Inhibitors Plus VEGFR Inhibitors
1
EGFR Mutation Positive Non-small Cell Lung Cancer
1
Drug-Related Side Effects and Adverse Reactions
1
Breast Neoplasms
1
Advanced Stage Non Small Cell Lung Cancer
1
Advanced Non-small Cell Lung Cancer
1
Advanced NSCLC With EGFR Mutation
1
Interventions
Gefitinib
1
Erlotinib Hydrochloride
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Advanced Stage Non Small Cell Lung Cancer
×
Gefitinib
×
Clear all
NCT01955421
2015-07-03
NSCLC EGFR TKI
Sun Yat-sen University
Phase 2
Unknown
224 enrolled